BioCentury | Jun 17, 2020
Product Development

U.K. approves steroid after master protocol shows survival benefit in COVID-19

...25 patients receiving oxygen would need to be treated with dexamethasone; ventilated patients had an NTT...
...death. Data from Gilead’s 584-patient Phase III SIMPLE study in moderate COVID-19, however, suggests an NTT...
BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...Inc. raised $60 million in a series B round from new investors Mayo Clinic and NTT...
BioCentury | Feb 2, 2009
Clinical News

SYI-2074: Phase II discontinued

...developed the topical cream formulation of the product for Synvista (see BioCentury, Jan. 21, 2008). Novel Therapeutic Technologies Inc....
BioCentury | Dec 22, 2008
Clinical News

SYI-2074: Phase II started

...Therapeutic developed the topical cream formulation of the product for Synvista (see BioCentury, Jan. 21). Novel Therapeutic Technologies Inc....
BioCentury | Jan 21, 2008
Company News

NTT, Synvista deal

...mimic from Oxis International Inc. (OTCBB:OXIS; Euronext:OXIS, Foster City, Calif.) (see BioCentury, April 16, 2007). Novel Therapeutic Technologies Inc....
Items per page:
1 - 5 of 5
BioCentury | Jun 17, 2020
Product Development

U.K. approves steroid after master protocol shows survival benefit in COVID-19

...25 patients receiving oxygen would need to be treated with dexamethasone; ventilated patients had an NTT...
...death. Data from Gilead’s 584-patient Phase III SIMPLE study in moderate COVID-19, however, suggests an NTT...
BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...Inc. raised $60 million in a series B round from new investors Mayo Clinic and NTT...
BioCentury | Feb 2, 2009
Clinical News

SYI-2074: Phase II discontinued

...developed the topical cream formulation of the product for Synvista (see BioCentury, Jan. 21, 2008). Novel Therapeutic Technologies Inc....
BioCentury | Dec 22, 2008
Clinical News

SYI-2074: Phase II started

...Therapeutic developed the topical cream formulation of the product for Synvista (see BioCentury, Jan. 21). Novel Therapeutic Technologies Inc....
BioCentury | Jan 21, 2008
Company News

NTT, Synvista deal

...mimic from Oxis International Inc. (OTCBB:OXIS; Euronext:OXIS, Foster City, Calif.) (see BioCentury, April 16, 2007). Novel Therapeutic Technologies Inc....
Items per page:
1 - 5 of 5